These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 26497595)
1. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units. Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595 [TBL] [Abstract][Full Text] [Related]
2. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725 [TBL] [Abstract][Full Text] [Related]
3. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients. Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465 [TBL] [Abstract][Full Text] [Related]
4. Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia. Chong YP; Park KH; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS Antimicrob Agents Chemother; 2015; 59(6):3541-7. PubMed ID: 25845875 [TBL] [Abstract][Full Text] [Related]
5. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital. da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China. Cheng X; Ma L; Wang Y; Sun W; Su J Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116180. PubMed ID: 38183897 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China. Wang Y; Hu YJ; Ai XM; Xu HT; Sun TY Chin Med J (Engl); 2013 Feb; 126(3):505-9. PubMed ID: 23422115 [TBL] [Abstract][Full Text] [Related]
9. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024 [TBL] [Abstract][Full Text] [Related]
10. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus]. Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013. Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398 [TBL] [Abstract][Full Text] [Related]
12. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. van Hal SJ; Jones M; Gosbell IB; Paterson DL PLoS One; 2011; 6(6):e21217. PubMed ID: 21713004 [TBL] [Abstract][Full Text] [Related]
13. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection. Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant Ozmen Capin BB; Tekeli A; Karahan ZC Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160 [No Abstract] [Full Text] [Related]
15. Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus. Harigaya Y; Ngo D; Lesse AJ; Huang V; Tsuji BT BMC Infect Dis; 2011 Oct; 11():287. PubMed ID: 22026752 [TBL] [Abstract][Full Text] [Related]
16. Molecular and Clinical Features of Heterogeneous Vancomycin-Intermediate Sreejisha M; Shenoy MS; Shenoy MS; Dhanashree B; Chakrapani M; Bhat KG Sultan Qaboos Univ Med J; 2023 Nov; 23(4):447-454. PubMed ID: 38090245 [TBL] [Abstract][Full Text] [Related]
17. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. Musta AC; Riederer K; Shemes S; Chase P; Jose J; Johnson LB; Khatib R J Clin Microbiol; 2009 Jun; 47(6):1640-4. PubMed ID: 19369444 [TBL] [Abstract][Full Text] [Related]
18. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital. Di Gregorio S; Perazzi B; Ordoñez AM; De Gregorio S; Foccoli M; Lasala MB; García S; Vay C; Famiglietti A; Mollerach M Microb Drug Resist; 2015 Feb; 21(1):25-34. PubMed ID: 25535825 [TBL] [Abstract][Full Text] [Related]
19. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China. Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362 [TBL] [Abstract][Full Text] [Related]